Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 424 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Enlivex Therapeutics Ltd | ENLV | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.27 | 09:12:14 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.27 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 23 | 424 | - | 1.15 - 4.59 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:23:07 | 1 | $ 1.3176 | USD |
Enlivex Therapeutics Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 23.39M | 18.42M | - | 0 | -31.06M | -1.69 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Enlivex Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ENLV Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.32 | 1.56 | 1.2301 | 1.43 | 199,278 | -0.05 | -3.79% |
| 1 Month | 4.11 | 4.59 | 1.15 | 2.11 | 375,171 | -2.84 | -69.10% |
| 3 Months | 2.57 | 4.59 | 1.15 | 2.53 | 177,666 | -1.30 | -50.58% |
| 6 Months | 1.36 | 4.59 | 1.15 | 2.56 | 127,011 | -0.09 | -6.62% |
| 1 Year | 2.91 | 4.59 | 1.15 | 2.52 | 75,707 | -1.64 | -56.36% |
| 3 Years | 9.94 | 13.95 | 1.15 | 6.83 | 86,470 | -8.67 | -87.22% |
| 5 Years | 8.67 | 44.90 | 1.15 | 9.87 | 161,969 | -7.40 | -85.35% |
Enlivex Therapeutics Description
| Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms. |
